Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nomen Azeem

Interventional Pain Medicine Riverview, FL Medical Doctor

NPI 1255594206 CMS profile 1139881

9360 Balm Riverview Rd, Riverview, FL 33569

Open in the dashboard

General payments

$650,199

1,937 records reported · program years 2019–2025

Research payments

$5,505

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$44,896

3 holdings reported · through program year 2025

Research they led as principal investigator

$32,839 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Nomen Azeem of Riverview, FL is reported in the CMS Open Payments database as having received $650,199 across 1,937 general payments and $5,505 in research payments paid to them. Separately, studies naming them as principal investigator received $32,839 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $44,896 across 3 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,969 187
2024 General $80,839 274
2023 General $66,733 222
2022 General $146,526 374
2022 Research $2,500 1
2021 General $113,715 302
2021 Research $3,005 2
2020 General $41,662 192
2019 General $169,756 386
2025 Ownership $7,796 1
2024 Ownership $22,300 1
2023 Ownership $14,800 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nomen Azeem
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Nomen Azeem were reported at $30,969. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Nomen Azeem Interventional Pain Medicine median Middle half National median
2019 $169,756 $684 $216–$2,079 $163
2020 $41,662 $382 $122–$1,109 $114
2021 $113,715 $552 $167–$1,554 $132
2022 $146,526 $605 $187–$1,924 $149
2023 $66,733 $671 $195–$1,915 $160
2024 $80,839 $684 $206–$1,837 $164
2025 $30,969 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vertiflex, Inc. $117,607 179 payments
  2. Spinal Simplicity, LLC $112,310 151 payments
  3. Medtronic, Inc. $108,904 404 payments
  4. Abbott Laboratories $108,731 477 payments
  5. Painteq LLC $84,388 284 payments
  6. Boston Scientific Corporation $47,535 142 payments
  7. Vertos Medical, Inc. $41,375 37 payments
  8. Globus Medical, Inc. $18,309 57 payments
  9. Nevro Corp. $2,263 54 payments
  10. SPR Therapeutics, Inc $1,710 17 payments
  11. Other $7,068 135 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $224,069 51 payments
  2. Consulting Fee $201,458 103 payments
  3. Travel and Lodging $81,756 244 payments
  4. Food and Beverage $67,045 1,490 payments
  5. Education $41,082 23 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $27,660 18 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $7,080 7 payments
  8. Entertainment $49 1 payment
Products named General payments · program years 2019–2025
  1. Superion ISS $117,607 179 payments
  2. HA MINUTEMAN G3-R $112,064 147 payments
  3. INTELLIS ADAPTIVESTIM $97,312 329 payments
  4. PAINTEQ $84,388 284 payments
  5. mild Device Kit $40,947 34 payments
  6. PROCLAIM $34,908 68 payments
  7. Neuromodulation Dspsbls and Accs $33,489 41 payments
  8. Proclaim Family of SCS IPGs $16,769 174 payments
  9. Senza $16,733 53 payments
  10. Axium INS DRG IPG $13,504 30 payments
  11. Other $76,557 582 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Painteq LLC $5,505 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

489

Median for Pain Management: 951

Drug cost

$23,522

Median for Pain Management: $26,034

Branded share of claims

20%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aimovig Autoinjector Erenumab-Aooe Brand 11 $9,967
Belbuca Buprenorphine Hcl Brand 12 $6,707
Pregabalin Generic 60 $2,167
Chlorzoxazone Generic 41 $1,484
Diclofenac Sodium Generic 67 $715
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 26 $691
Gabapentin Generic 69 $557
Methylprednisolone Generic 52 $373
Methocarbamol Generic 35 $338
Celecoxib Generic 24 $221

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$152,757

Of which drugs: $142

Medicare patients

179

Average age 73

Services billed

1,812

108 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Ischemic heart disease 37%
Depression 34%
Diabetes 28%
Osteoporosis 26%
COPD 25%
Chronic kidney disease 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 29 160 $124
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 130 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$16 — —
BOTOX
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,940 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record